Endometriosis study seeks the most satisfying hormone combo

NCT ID NCT07204093

Ongoing Disease control Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at two different hormone combinations for treating endometriosis: drospirenone plus estradiol, or dienogest plus estradiol. Researchers want to know which one women are more satisfied with after six months of use. The study involves 138 women and focuses on patient preference and symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Drospirenone 4 mg orally plus transdermal estradiol, or Dienogest 2 mg orally plus transdermal estradiol
What this could lead to: If successful, this could help doctors choose the hormone therapy that women with endometriosis find most satisfying, improving long-term treatment adherence.
What could go wrong: This is a small, observational study comparing existing treatments, not testing a new drug. Results may not apply to all women, and satisfaction is subjective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS

Contacts and locations

Locations

Gynecology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.